基于片段的程序性死亡配体 1（PD-L1）筛选。
Fragment-based screening of programmed death ligand 1 (PD-L1).
机构信息
Department of Biochemistry, Vanderbilt University, Nashville, TN 37232-0146, USA.
Vanderbilt Institute of Chemical Biology Synthesis Core, Vanderbilt University, Nashville, TN 37232-0146, USA.
出版信息
Bioorg Med Chem Lett. 2019 Mar 15;29(6):786-790. doi: 10.1016/j.bmcl.2019.01.028. Epub 2019 Jan 24.
Abstract
The PD-1 immune checkpoint pathway is a highly validated target for cancer immunotherapy. Despite the potential advantages of small molecule inhibitors over antibodies, the discovery of small molecule checkpoint inhibitors has lagged behind. To discover small molecule inhibitors of the PD-1 pathway, we have utilized a fragment-based approach. Small molecules were identified that bind to PD-L1 and crystal structures of these compounds bound to PD-L1 were obtained.
摘要
PD-1 免疫检查点途径是癌症免疫治疗的一个高度验证的靶点。尽管小分子抑制剂相对于抗体具有潜在的优势，但小分子检查点抑制剂的发现却落后了。为了发现 PD-1 途径的小分子抑制剂，我们利用了基于片段的方法。已经鉴定出了与 PD-L1 结合的小分子，并且获得了这些化合物与 PD-L1 结合的晶体结构。
相似文献
1
Fragment-based screening of programmed death ligand 1 (PD-L1).基于片段的程序性死亡配体 1（PD-L1）筛选。
Bioorg Med Chem Lett. 2019 Mar 15;29(6):786-790. doi: 10.1016/j.bmcl.2019.01.028. Epub 2019 Jan 24.
2
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).程序性死亡配体1（PD-L1）小分子靶向的结构基础
Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730.
3
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.通过瞬时诱导的蛋白质状态和 PD-L1 二聚化来抑制程序性细胞死亡-1/程序性死亡配体 1（PD-1/PD-L1）相互作用的小分子抑制剂。
J Med Chem. 2017 Jul 13;60(13):5857-5867. doi: 10.1021/acs.jmedchem.7b00293. Epub 2017 Jun 23.
4
Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.用片段分子轨道法研究 PD-1 和 PD-L1 之间的蛋白质-蛋白质相互作用和热点区域。
Sci Rep. 2019 Nov 13;9(1):16727. doi: 10.1038/s41598-019-53216-z.
5
Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.基于对称性的配体设计及程序性细胞死亡蛋白 1/程序性死亡配体 1 相互作用小分子抑制剂的评价。
Bioorg Med Chem Lett. 2019 Sep 1;29(17):2464-2467. doi: 10.1016/j.bmcl.2019.07.027. Epub 2019 Jul 17.
6
Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.发现苯环连接的对称小分子作为程序性细胞死亡-1/程序性细胞死亡配体 1 相互作用抑制剂。
Eur J Med Chem. 2021 Nov 5;223:113637. doi: 10.1016/j.ejmech.2021.113637. Epub 2021 Jun 11.
7
PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.PD-1/PD-L1 抑制剂在肿瘤免疫治疗中的应用：从抗体到小分子。
Curr Pharm Des. 2018 Feb 12;23(39):6033-6041. doi: 10.2174/1381612823666171004120152.
8
Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.通过结构简化策略发现 PD-1/PD-L1 相互作用的新型小分子抑制剂。
Molecules. 2021 Jun 2;26(11):3347. doi: 10.3390/molecules26113347.
9
Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.采用结构导向方法，针对 PD-L1 的隐匿正构位点进行抑制剂鉴定。
Arch Biochem Biophys. 2021 Nov 30;713:109059. doi: 10.1016/j.abb.2021.109059. Epub 2021 Oct 18.
10
Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors.PD-L1 调节剂的最新进展：降解剂、下调剂和共价抑制剂。
J Med Chem. 2020 Dec 24;63(24):15389-15398. doi: 10.1021/acs.jmedchem.0c01362. Epub 2020 Dec 4.
引用本文的文献
1
Immunoinformatics based designing of a multi-epitope cancer vaccine targeting programmed cell death ligand 1.基于免疫信息学设计靶向程序性细胞死亡配体1的多表位癌症疫苗。
Sci Rep. 2025 Apr 11;15(1):12420. doi: 10.1038/s41598-025-87063-y.
2
Drugging Challenging Cancer Targets Using Fragment-Based Methods.利用基于片段的方法靶向治疗具有挑战性的癌症靶点。
Chem Rev. 2025 Mar 26;125(6):3586-3594. doi: 10.1021/acs.chemrev.4c00892. Epub 2025 Mar 5.
3
Perspectives on Applications of F-NMR in Fragment-Based Drug Discovery.F-核磁共振在基于片段的药物发现中的应用前景
Molecules. 2024 Dec 5;29(23):5748. doi: 10.3390/molecules29235748.
4
-driven identification of Pranlukast as a Stabilizer of PD-L1 Homodimers.驱动识别普仑司特作为PD-L1同型二聚体的稳定剂。
Anticancer Agents Med Chem. 2025;25(3):179-193. doi: 10.2174/0118715206303675241009104647.
5
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.C2-对称三联苯衍生物作为程序性细胞死亡 1/程序性死亡配体 1 蛋白-蛋白相互作用的小分子抑制剂。
Molecules. 2024 Jun 4;29(11):2646. doi: 10.3390/molecules29112646.
6
In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors.探索更好的基于肽（来源于 PD-L2）的免疫检查点抑制剂。
Biomolecules. 2024 May 18;14(5):597. doi: 10.3390/biom14050597.
7
Progress in small-molecule inhibitors targeting PD-L1.靶向程序性死亡配体1（PD-L1）的小分子抑制剂的研究进展
RSC Med Chem. 2024 Mar 4;15(4):1161-1175. doi: 10.1039/d3md00655g. eCollection 2024 Apr 24.
8
A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules.对程序性死亡配体1（PD-L1）与程序性死亡受体1（PD-1）及小分子结合的全面计算洞察
Pharmaceuticals (Basel). 2024 Feb 28;17(3):316. doi: 10.3390/ph17030316.
9
Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers.利用专利数据的非活性增强型机器学习模型改进了基于结构的PDL1二聚体虚拟筛选。
J Adv Res. 2025 Jan;67:185-196. doi: 10.1016/j.jare.2024.01.024. Epub 2024 Jan 26.
10
Effect of Fragment 1 on the Binding of Epigallocatechin Gallate to the PD-L1 Dimer Explored by Molecular Dynamics.分子动力学探究 Fragment 1 对 EGCG 与 PD-L1 二聚体结合的影响。
Molecules. 2023 Nov 30;28(23):7881. doi: 10.3390/molecules28237881.
本文引用的文献
1
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.PD-1 和 PD-L1 抑制剂作为癌症免疫疗法的一种形式的发展：注册试验的综合回顾和未来的考虑。
J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z.
2
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.PD-1/PD-L1免疫检查点的小分子抑制剂可缓解PD-L1诱导的T细胞耗竭。
Oncotarget. 2017 Aug 7;8(42):72167-72181. doi: 10.18632/oncotarget.20050. eCollection 2017 Sep 22.
3
Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.生物活性大环 PD-1/PD-L1 免疫检查点抑制剂。
Angew Chem Int Ed Engl. 2017 Oct 23;56(44):13732-13735. doi: 10.1002/anie.201707707. Epub 2017 Sep 26.
4
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.免疫检查点受体 PD-1 及其配体 PD-L1/PD-L2 的结构生物学。
Structure. 2017 Aug 1;25(8):1163-1174. doi: 10.1016/j.str.2017.06.011.
5
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.通过瞬时诱导的蛋白质状态和 PD-L1 二聚化来抑制程序性细胞死亡-1/程序性死亡配体 1（PD-1/PD-L1）相互作用的小分子抑制剂。
J Med Chem. 2017 Jul 13;60(13):5857-5867. doi: 10.1021/acs.jmedchem.7b00293. Epub 2017 Jun 23.
6
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗诱导的免疫相关不良事件（irAEs）的当前诊断与管理
Front Pharmacol. 2017 Feb 8;8:49. doi: 10.3389/fphar.2017.00049. eCollection 2017.
7
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.与免疫检查点抑制剂相关的免疫相关不良事件。
BioDrugs. 2016 Dec;30(6):571-584. doi: 10.1007/s40259-016-0204-3.
8
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).程序性细胞死亡蛋白1（PD-1）抑制剂：专利综述（2010 - 2015年）
Expert Opin Ther Pat. 2016 Sep;26(9):973-7. doi: 10.1080/13543776.2016.1206527. Epub 2016 Jul 6.
9
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).程序性死亡配体1（PD-L1）小分子靶向的结构基础
Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730.
10
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.免疫检查点阻断相关的免疫相关不良事件：一项全面综述。
Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5.
Zotero 插件